コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nal coronary angioplasty and coronary artery bypass graft surgery).
2 ous coronary angioplasty and coronary artery bypass graft surgery.
3 comes in patients undergoing coronary artery bypass graft surgery.
4 of 4224 patients undergoing coronary artery bypass graft surgery.
5 ct long-term mortality after coronary artery bypass graft surgery.
6 ) in 492 patients undergoing coronary artery bypass graft surgery.
7 r early SVG thrombosis after coronary artery bypass graft surgery.
8 s in 218 patients undergoing coronary artery bypass graft surgery.
9 ients undergoing nonemergent coronary artery bypass graft surgery.
10 ous coronary intervention or coronary artery bypass graft surgery.
11 1 (9.1%) patients undergoing coronary artery bypass graft surgery.
12 of whites undergoing primary coronary artery bypass graft surgery.
13 0% of patients who underwent coronary artery bypass graft surgery.
14 in whites undergoing primary coronary artery bypass graft surgery.
15 (PMI) in patients undergoing coronary artery bypass graft surgery.
16 cardial infarction following coronary artery bypass graft surgery.
17 ns during and after off-pump coronary artery bypass graft surgery.
18 on, or previous multi-vessel coronary artery bypass graft surgery.
19 or short-term sedation after coronary artery bypass graft surgery.
20 and morbidity compared with on-pump coronary bypass graft surgery.
21 gnificant complication after coronary artery bypass graft surgery.
22 from 39 patients undergoing coronary artery bypass graft surgery.
23 a common complication after coronary artery bypass graft surgery.
24 mmon cause of bleeding after coronary artery bypass graft surgery.
25 on in the need for emergency coronary artery bypass graft surgery.
26 ecipitate transfusions after coronary artery bypass graft surgery.
27 .2, p =.04) transfused after coronary artery bypass graft surgery.
28 bleeding complications after coronary artery bypass graft surgery.
29 likely to have prior PCI or coronary artery bypass graft surgery.
30 ts before, and for 5 days following, cardiac bypass graft surgery.
31 102 women, who had undergone coronary artery bypass graft surgery.
32 d septic shock, and low-risk coronary artery bypass graft surgery.
33 ment depression and previous coronary artery bypass graft surgery.
34 ) more sites were performing coronary artery bypass graft surgery.
35 erapy or in combination with coronary artery bypass graft surgery.
36 coronary syndromes and after coronary artery bypass graft surgery.
37 pofol for patient undergoing coronary artery bypass graft surgery.
38 tients (77%) had concomitant coronary artery bypass graft surgery.
39 s in sinus rhythm undergoing coronary artery bypass graft surgery.
40 at operations after previous coronary artery bypass graft surgery.
41 major bleeding unrelated to coronary artery bypass graft surgery.
42 nd stroke when compared with coronary artery bypass graft surgery.
43 -term risk of mortality with coronary artery bypass graft surgery.
44 percutaneous coronary intervention (PCI) and bypass graft surgery.
45 ) were deemed ineligible for coronary artery bypass graft surgery.
46 l failure), and a history of coronary artery bypass graft surgery.
47 were men, and 30% had prior coronary artery bypass graft surgery.
48 ared with angiography-guided coronary artery bypass graft surgery.
49 s known about candidates for coronary artery bypass graft surgery.
50 sinus rhythm, and undergoing coronary artery bypass graft surgery.
51 it the long-term efficacy of coronary artery bypass graft surgery.
52 neous intervention, and redo coronary artery bypass graft surgery.
53 and long-term outcomes after coronary artery bypass graft surgery.
54 uded 677 patients undergoing coronary artery bypass graft surgery.
55 diabetes and were undergoing coronary artery bypass grafting surgery.
56 patients undergoing isolated coronary artery bypass grafting surgery.
57 orbidity and mortality after coronary artery bypass grafting surgery.
59 major bleeding unrelated to coronary artery bypass graft surgery (1.6% vs 2.3%, RR 0.67, 95% CI 0.49
60 risk for repeat procedures (coronary artery bypass graft surgery: 10.7% versus 6.8%, P=0.04, adjuste
61 ase (64.4% vs. 83.7%), prior coronary artery bypass graft surgery (19.8% vs. 61.2%), peripheral vascu
62 dial infarction, or emergent coronary artery bypass graft surgery [2.8% versus 3.3%]), although creat
63 .28 to 2.72]; P < .001), and coronary artery bypass graft surgery (3.7% vs 1.3%; AOR, 3.00 [2.63 to 3
65 ercent, P < or = 0.001); and coronary-artery bypass graft surgery (35.0 percent vs. 11.1 percent, P <
67 39%, P<0.0001) and both post-coronary artery bypass graft surgery (38%, P=0.048) and post-PCI (57%, P
68 myocardial infarction (MI) (45.8%), coronary bypass graft surgery (39.2%), chronic renal failure (18.
69 .5%) occurred, including 140 coronary artery bypass graft surgeries (4.1%) and 114 percutaneous coron
71 ; p=0.04), and major bleeding not related to bypass graft surgery (6.9%vs 10.5%, -3.6% [-5.5 to -1.7]
72 WCDs (90-day mortality post-coronary artery bypass graft surgery 7% versus 3%, P=0.03; post-PCI 10%
73 el or target lesion failure (coronary artery bypass graft surgery: 8.9% versus 3.9%, P<0.001, adjuste
74 eatment assignment, and years since coronary bypass graft surgery, a CES-D score > or =16 was positiv
75 three-vessel disease, prior coronary artery bypass graft surgery, a history of hypertension, or a re
76 igher in patients undergoing coronary artery bypass graft surgery after 4 wk of consuming a low-GI di
77 PMI in whites after primary coronary artery bypass graft surgery after adjustment for other covariat
78 -perceived satisfaction with coronary artery bypass graft surgery after administration of DEX or prop
79 is paucity of data comparing coronary artery bypass graft surgery against newer generation stents.
80 ation, of whom 264 underwent coronary artery bypass graft surgery and 487 underwent percutaneous coro
84 the risk of mortality after coronary artery bypass graft surgery and can be used for informed consen
85 es of in-hospital Q-wave MI, coronary artery bypass graft surgery and death were 0.4%, 1.9% and 1.4%,
86 lated from vein leftovers of coronary artery bypass graft surgery and discarded atrial specimens of t
87 1829 patients who underwent coronary artery bypass graft surgery and had an angiogram performed up t
88 beneficiaries undergoing any coronary artery bypass graft surgery and higher observed mortality rates
90 erse clinical outcomes after coronary artery bypass graft surgery and myocardial infarction in women.
91 tus and multivessel disease, coronary artery bypass graft surgery and percutaneous coronary intervent
92 coronary revascularization (coronary artery bypass graft surgery and percutaneous transluminal coron
93 of abrupt closure, emergency coronary artery bypass graft surgery and restenosis, but do not prevent
94 m a myocardial infarction or coronary artery bypass graft surgery and those with severe heart failure
96 inal aortic aneurysm repair, coronary artery bypass graft surgery, and craniotomy, and for RS of 4 po
97 als, no smoking, no previous coronary artery bypass graft surgery, and left anterior descending arter
99 eath, myocardial infarction, coronary artery bypass graft surgery, and repeat PCI were primary outcom
100 graphy 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes.
101 cTnT concentrations after coronary artery bypass graft surgery are nearly universally elevated, ar
102 rvival prediction models for coronary artery bypass grafting surgery are limited to in-hospital or 30
103 ous coronary intervention or coronary artery bypass graft surgery as appropriate) plus GDMT reduces r
104 patients undergoing elective coronary artery bypass graft surgery at a single tertiary centre could b
105 patients undergoing isolated coronary artery bypass grafting surgery at 33 medical centers in Michiga
106 pool of patients undergoing coronary artery bypass grafting surgery at the remaining hospitals and f
107 tcome of patients undergoing coronary artery bypass graft surgery beneficially by producing superlati
108 4-1.04; P<0.001); history of coronary artery bypass graft surgery (beta=1.32; CI, 1.28-1.32; P<0.001)
109 o compare change in rates of coronary artery bypass graft surgery between 2002 to 2003 and 2008 to 20
110 undergoing isolated off-pump coronary artery bypass graft surgery between January 2000 and June 2002.
111 us coronary intervention, or coronary artery bypass graft surgery between January 2000 and September
112 .9%; AVR + CABG) concomitant coronary artery bypass graft surgery between November 10, 1987 through J
113 ailure (VGF) is common after coronary artery bypass graft surgery, but its relationship with long-ter
114 ) should be standard care in coronary artery bypass graft surgery, but vein quality and clinical outc
115 -cause readmission following coronary artery bypass grafting surgery by using nationally representati
116 ion (MI) (2.3% vs. 3.0%) and coronary artery bypass graft surgery (CABG) (1.3% vs. 1.4%) were similar
117 oplasty (PTCA) (n = 834) and coronary artery bypass graft surgery (CABG) (n = 1805) in diabetic patie
119 on (PCI) with survival after coronary artery bypass graft surgery (CABG) among diabetics in the Veter
120 cs of patients with previous coronary artery bypass graft surgery (CABG) and acute myocardial infarct
121 ed guidelines for the use of coronary artery bypass graft surgery (CABG) and percutaneous coronary in
122 term survival and subsequent coronary artery bypass graft surgery (CABG) and percutaneous coronary in
123 rdiac serum biomarkers after coronary artery bypass graft surgery (CABG) are associated with increase
124 onary intervention (PCI) and coronary artery bypass graft surgery (CABG) are being applied to high-ri
126 term survival advantage with coronary artery bypass graft surgery (CABG) compared with percutaneous t
127 s in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platele
128 ntly, the need for emergency coronary artery bypass graft surgery (CABG) decreased significantly (p(t
129 nts with heart failure after coronary artery bypass graft surgery (CABG) has not been examined in a c
130 National risk models for coronary artery bypass graft surgery (CABG) have gained widespread accep
132 ronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in physician-directed and pa
133 rial fibrillation (AF) after coronary artery bypass graft surgery (CABG) is associated with increased
136 he likelihood of in-hospital coronary artery bypass graft surgery (CABG) might be useful in selecting
137 ted that public reporting of coronary artery bypass graft surgery (CABG) mortality might result in ca
138 on during minimally invasive coronary artery bypass graft surgery (CABG) on hemodynamic variables and
139 atients who underwent repeat coronary artery bypass graft surgery (CABG) or percutaneous coronary int
141 tive beta-blocker therapy on coronary artery bypass graft surgery (CABG) outcomes has not been assess
145 d 389 patients; 312 had only coronary artery bypass graft surgery (CABG) surgery, 37 had both valve a
146 tinitis is a complication of coronary artery bypass graft surgery (CABG) that can be difficult to dia
147 s a frequent complication of coronary artery bypass graft surgery (CABG) that leads to increased cost
148 ain coronary artery disease, coronary artery bypass graft surgery (CABG) was associated with a lower
149 s With Diabetes) trial found coronary artery bypass graft surgery (CABG) was associated with better c
150 Current guidelines recommend coronary artery bypass graft surgery (CABG) when treating significant de
151 Randomized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous coronary i
152 randomized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous translumin
153 et of stroke occurring after coronary artery bypass graft surgery (CABG) without cardiopulmonary bypa
154 serious complications after coronary artery bypass graft surgery (CABG), and their etiology and impl
155 al adverse outcomes included coronary artery bypass graft surgery (CABG), myocardial infarction (MI)
156 al adverse outcomes included coronary artery bypass graft surgery (CABG), myocardial infarction and m
157 ronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), should these interventions
158 among patients treated with coronary artery bypass graft surgery (CABG), we evaluated the impact of
175 nsecutive patients underwent coronary artery bypass graft surgery (CABG); all received RA and left in
178 ring cardiopulmonary bypass (coronary artery bypass graft surgery [CABG]) in a broad cross section of
179 surgical revascularization (coronary artery bypass graft surgery [CABG]) versus TAXUS Express (Bosto
180 ronary intervention [PCI] vs coronary artery bypass graft surgery [CABG]) were prospectively selected
181 ronary angioplasty [PTCA] or coronary artery bypass graft surgery [CABG]), the primary trial end poin
183 oup of patients intended for coronary artery bypass graft surgery compared with the subgroup intended
185 ed angina (1.91; 1.59-2.29), coronary artery bypass graft surgery/coronary angioplasty procedure/sten
187 luding younger age, previous coronary artery bypass graft surgery, depressive symptoms, and financial
190 es included death, emergency coronary artery bypass graft surgery (eCABG), non-emergency CABG (non-eC
191 between off-pump and on-pump coronary artery bypass graft surgery for follow-up longer than 5 years i
192 s effect of P4P on access to coronary artery bypass graft surgery for high-risk patients with AMI.
193 nts who had isolated primary coronary artery bypass graft surgery for multivessel coronary artery dis
196 enzyme inhibitors (ACEIs) in coronary artery bypass graft surgery has been erratic and controversial.
197 enal failure associated with coronary artery bypass graft surgery has significantly increased from 19
198 secutive patients treated by coronary artery bypass graft surgery having at least 1 angiographically
199 on (CR) is recommended after coronary artery bypass graft surgery; however, the consequences of longe
200 ease improves survival after coronary artery bypass graft surgery; however, the survival benefit of m
201 inate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial, a phase 3, multicenter, r
202 als that performed 1 or more coronary artery bypass graft surgeries in a given calendar year were cla
204 ed 3 days and 6 months after coronary artery bypass graft surgery in 229 subjects receiving aspirin m
205 te myocardial infarctions or coronary artery bypass graft surgery in 267,427 fee-for-service benefici
207 ients who underwent isolated coronary artery bypass graft surgery in July through December 2000.
208 ronary syndromes or previous coronary artery bypass graft surgery in periods before (2010 through 201
210 re misclassified as isolated coronary artery bypass grafting surgery in the administrative cohort.
211 -risk patients who underwent coronary artery bypass graft surgery, in whom both prerequisites could b
212 us coronary intervention and coronary artery bypass graft surgery independently contributed to the si
214 awal of ACEI treatment after coronary artery bypass graft surgery is associated with nonfatal in-hosp
215 Autologous saphenous vein coronary artery bypass graft surgery is complicated by late graft failur
216 enal failure associated with coronary artery bypass graft surgery is increasing in the United States.
217 between on-pump and off-pump coronary artery bypass graft surgery is not statistically significant.
220 nce Database associated with coronary artery bypass graft surgery, myocardial infarction/cardiogenic
222 idence interval, 0.55-0.67), coronary artery bypass graft surgery (n=1077; hazard ratio, 0.68; 95% co
223 body mass index, history of coronary artery bypass graft surgery, number of treated lesions, and chr
225 fter adjustment for hospital coronary artery bypass graft surgery or cardiac catheterization capabili
226 method of revascularization, coronary artery bypass graft surgery or percutaneous coronary interventi
227 pital mortality after either coronary artery bypass graft surgery or percutaneous coronary interventi
228 arization by procedure type (coronary artery bypass graft surgery or percutaneous coronary interventi
229 served-to-expected ratio for coronary artery bypass graft surgery or percutaneous coronary interventi
230 litus and underwent isolated coronary artery bypass graft surgery or percutaneous coronary interventi
231 revascularization procedure: coronary artery bypass graft surgery or percutaneous coronary interventi
232 ina who are not suitable for coronary artery bypass graft surgery or percutaneous transluminal corona
234 ent without death, emergency coronary artery bypass graft surgery or Q wave myocardial infarction.
235 with coronary angioplasty or coronary artery bypass graft surgery or were treated with calcium channe
236 likelihood of ACEI/ARB after coronary artery bypass grafting surgery or in patients with renal insuff
237 0.95), and those undergoing coronary artery bypass graft surgery (OR 0.58; 95% CI 0.55 to 0.60).
238 al survivors after surgical (coronary artery bypass graft surgery) or percutaneous (percutaneous coro
239 farction, emergent or urgent coronary artery bypass graft surgery, or cerebrovascular accident after
241 ll-cause death, MI, emergent coronary artery bypass graft surgery, or target lesion revascularization
242 olar lavage fluid rose after coronary artery bypass graft surgery (p < 0.05), but there was no signif
243 th lower mortality (58% post-coronary artery bypass graft surgery, P=0.002; 67% post-PCI, P<0.0001).
244 alysis of 47 984 consecutive coronary artery bypass grafting surgeries performed from 1992 to 2014 am
245 Society of Thoracic Surgeons coronary artery bypass graft surgery population studied, the median age
246 x, both clinically (previous coronary artery bypass graft surgery prevalence, 48% versus 24%; P<0.001
248 Among patients selected for coronary artery bypass graft surgery, prompt coronary revascularization
249 risk-adjusted mortality for coronary artery bypass graft surgery, public reporting on outcomes has e
250 -hospital death, in-hospital coronary artery bypass graft surgery, Q wave myocardial infarction) were
251 ronary angiography rates and coronary artery bypass graft surgery rates (R(2)=0.41) with the suggesti
257 Fiscal year 2003 isolated coronary artery bypass grafting surgery results based on an audited and
258 ascularization among the 381 coronary artery bypass graft surgery-selected patients in the highest an
259 isease, a strategy of prompt coronary artery bypass graft surgery significantly reduces the rate of d
261 aphic risk groups within the coronary artery bypass graft surgery stratum, or in any subgroups within
263 ocardial infarction, angina, coronary artery bypass graft surgery, stroke, claudication, gangrene, or
264 aphenous vein grafts used in coronary artery bypass graft surgery suffer from lower patency rates com
266 ains a major complication of coronary artery bypass graft surgery that is strongly associated with in
267 e coronary syndrome/no prior coronary artery bypass graft surgery that were rated as inappropriate de
269 utcomes of TMR combined with coronary artery bypass graft surgery (TMR + CABG) versus bypass alone in
270 ndomized patients with a history of coronary bypass graft surgery to either an aggressive or a modera
271 patients undergoing off-pump coronary artery bypass graft surgery using a large patient sample and a
272 rgoing nonemergent, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass by
273 27.4% disparity in isolated coronary artery bypass grafting surgery volume (4440 clinical, 5657 admi
277 cardial infarction following coronary artery bypass graft surgery was associated with a significant i
278 alysis reported that EVH for coronary artery bypass graft surgery was associated with worse outcomes
283 bleeding not associated with coronary artery bypass graft surgery were also increased among patients
284 ammary artery (IMA) of 7 patients undergoing bypass graft surgery were assessed for IL-8 content by s
287 patients undergoing elective coronary artery bypass graft surgery were randomized to atorvastatin 40
288 rillation and indication for coronary artery bypass graft surgery were randomized to botulinum toxin
289 Sixty patients undergoing coronary artery bypass graft surgery were randomized to RIPC (n=30) or c
290 patients undergoing elective coronary artery bypass graft surgery were randomly assigned to either a
291 rdiac interventions, such as coronary artery bypass graft surgery, were also included, totaling 362 p
292 vidence that patients having coronary artery bypass graft surgeries with an internal mammary artery (
293 ed patients before and after coronary artery bypass graft surgery with cardiopulmonary bypass and lob
294 ptive study of 4801 patients having coronary bypass graft surgery with cardiopulmonary bypass from No
295 undergoing primary elective coronary artery bypass graft surgery with cardiopulmonary bypass to dete
297 yocardial stunning following coronary artery bypass graft surgery with cardiopulmonary bypass, it red
298 =60) underwent jugular-carotid interposition bypass graft surgery with intraoperative adenoviral gene
299 patients undergoing isolated coronary artery bypass graft surgery with LIMA to left anterior descendi
300 g the study population, 1482 coronary artery bypass grafting surgeries with BIMA were identified, and
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。